ArticleJournal of materials science. Materials in medicine2025
The potential of Eco-friendly synthesis of multifunctional ZnO-CuO nanocomposites using Mentha longifolia extract for their biomedical applications.
Article in Journal of materials science. Materials in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
In this study, we report the biogenic synthesis of ZnO-CuO nanocomposites (NCPs) utilizing Mentha longifolia leaf extract as both a reducing and capping candidate. The synthesis process was optimized utilizing the Plackett-Burman statistical design, achieving a maximum yield of 22.18 mg/mL under controlled conditions. The resulting ZnO-CuO NCPs exhibited a crystalline structure with an average particle size of 26.61 nm, as analyzed by XRD, TEM, and SEM approaches. FTIR spectroscopy demonstrated the presence of bioactive phytoconstituents, such as phenolic derivatives and alkaloids, which stabilized the nanocomposites. The ZnO-CuO NCPs demonstrated potent antimicrobial activity against multidrug-resistant pathogens, including Staphylococcus aureus, Escherichia coli, and Candida albicans, with a minimum inhibitory concentration (MIC) of 180.47 µg/mL. In anticancer evaluations, the ZnO-CuO NCPs exhibited selective cytotoxicity against A549 (lung), HepG2 (liver), and MDA (breast) cancer cell lines, with selectivity indices (SI) of 4.88, 25.19, and 46.32, respectively. Apoptosis induction was confirmed through nuclear staining and morphological analysis. Additionally, the ZnO-CuO NCPs showed promising antiviral activity against herpes simplex virus-1 (HSV-1) (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.